Cell Source, Inc. announced advancements in its immune tolerance technology, expanding clinical trials for mismatched donor stem cell and kidney transplants without ongoing immune suppression, alongside off-the-shelf CAR-T cell therapy. The company plans to uplist to NASDAQ to support funding for these developments. Their Veto Cell technology, licensed from The Weizmann Institute, aims to improve safety and accessibility in transplant and cancer treatments. This move aligns with trends of major oncology acquisitions and could enhance treatment options for blood cancers and autoimmune diseases.
Virtuals Protocol has introduced customizable tokenized indexes on the Robinhood Chain, allowing users to combine multiple assets into a single token. This innovation enables users to create and manage their own asset baskets and earn fees when other...
US spot Bitcoin ETFs saw net inflows of $107.8 million on Wednesday, while Ethereum ETFs attracted $53.8 million, signaling renewed institutional interest in crypto funds. Since their launch in January 2024, Bitcoin ETFs have accumulated over $51 bil...
Kaia has signed a strategic partnership with Xilo Labs to integrate Mochi, an onchain asset management platform, into Kaia's ecosystem. This collaboration allows users to invest stablecoins into diversified portfolios backed by tokenized real-world a...
Bitcoin's price surged to nearly $65,000 following softer-than-expected U.S. inflation data for June, easing fears of Federal Reserve rate hikes. However, on-chain data reveals two main groups of investors—long-term holders who bought near last year'...
Bitcoin miners are experiencing declining revenue as the network's hash rate and mining difficulty fall, reflecting a shift of miners into AI infrastructure. Despite this stress, miners are accumulating Bitcoin, with reserves increasing by 1%, signal...
